1. Home
  2. NSPR vs DLHC Comparison

NSPR vs DLHC Comparison

Compare NSPR & DLHC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NSPR
  • DLHC
  • Stock Information
  • Founded
  • NSPR 2005
  • DLHC 1969
  • Country
  • NSPR United States
  • DLHC United States
  • Employees
  • NSPR N/A
  • DLHC N/A
  • Industry
  • NSPR Medical/Dental Instruments
  • DLHC Business Services
  • Sector
  • NSPR Health Care
  • DLHC Consumer Discretionary
  • Exchange
  • NSPR Nasdaq
  • DLHC Nasdaq
  • Market Cap
  • NSPR 74.8M
  • DLHC 79.6M
  • IPO Year
  • NSPR N/A
  • DLHC N/A
  • Fundamental
  • Price
  • NSPR $2.69
  • DLHC $5.52
  • Analyst Decision
  • NSPR Strong Buy
  • DLHC
  • Analyst Count
  • NSPR 2
  • DLHC 0
  • Target Price
  • NSPR $4.50
  • DLHC N/A
  • AVG Volume (30 Days)
  • NSPR 109.3K
  • DLHC 23.8K
  • Earning Date
  • NSPR 08-05-2025
  • DLHC 08-06-2025
  • Dividend Yield
  • NSPR N/A
  • DLHC N/A
  • EPS Growth
  • NSPR N/A
  • DLHC 75.08
  • EPS
  • NSPR N/A
  • DLHC 0.38
  • Revenue
  • NSPR $7,027,000.00
  • DLHC $377,074,000.00
  • Revenue This Year
  • NSPR $4.85
  • DLHC N/A
  • Revenue Next Year
  • NSPR $113.47
  • DLHC N/A
  • P/E Ratio
  • NSPR N/A
  • DLHC $14.71
  • Revenue Growth
  • NSPR 8.49
  • DLHC N/A
  • 52 Week Low
  • NSPR $1.99
  • DLHC $2.72
  • 52 Week High
  • NSPR $3.80
  • DLHC $11.42
  • Technical
  • Relative Strength Index (RSI)
  • NSPR 62.76
  • DLHC 45.31
  • Support Level
  • NSPR $2.37
  • DLHC $5.68
  • Resistance Level
  • NSPR $2.92
  • DLHC $5.92
  • Average True Range (ATR)
  • NSPR 0.16
  • DLHC 0.18
  • MACD
  • NSPR 0.03
  • DLHC -0.04
  • Stochastic Oscillator
  • NSPR 66.18
  • DLHC 4.44

About NSPR InspireMD Inc.

InspireMD Inc is a United States based medical device company. It is focused on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of complex vascular and coronary disease. The products of the company are the CGuard carotid Embolic Prevention System (CGuard EPS) and the MGuard Prime Embolic Protection System (MGuard Prime EPS). It generates the majority of the revenue from the sales of CGuard EPS which combines MicroNet and a self-expandable nitinol stent in a single device for use in carotid artery applications. The group operates in Italy, Germany, Russia and other countries.

About DLHC DLH Holdings Corp.

DLH Holdings Corp is a provider of technology-enabled business process outsourcing and program management solutions in the United States. The company offers services to several government agencies which include the Department of Veteran Affairs. The company is engaged in public health, performance evaluation, and health operations to solve the complex problems faced by civilian and military customers alike, leveraging digital transformation, artificial intelligence, analytics, cloud-based applications, telehealth systems, and others.

Share on Social Networks: